Second Quarter Results to June 30, 2010

Shire plc
August 4, 2010

Angus Russell
Chief Executive Officer

Michael Cola
President, Specialty Pharmaceuticals

Graham Hetherington
Chief Financial Officer

Sylvie Grégoire
President, Human Genetic Therapies

Shire

Our purpose
We enable people with life-altering conditions to lead better lives

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of Shire's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure new products for commercialization and/or development; government regulation of Shire's products; Shire's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on Shire's products; Shire's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; Shire's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in Shire's filings with the Securities and Exchange Commission.

Agenda

• Opening remarks	Angus Russell
• Financial review	Graham Hetherington
• Specialty Pharma update	Michael Cola
• HGT update	Sylvie Grégoire
• Concluding remarks	Angus Russell
• Q & A	All

Opening remarks

Angus Russell
CEO

Our purpose
We enable people with life-altering conditions to lead better lives

Shire Performing Well on All Fronts

- Excellent Q2 performance
- Total revenues up 35% to $849 million
  - Revenues now ahead of pre-AXR authorized generic levels after just 15 months
- Core product sales(1) $684 million - up 39%
- Non GAAP diluted earnings per ADS: $1.03
  - Up 71% versus Q2 2009
- Strong cash generation of $416 million
- Dividend up 5% in US Dollar terms

(1) Core products represent Shire's products excluding ADDERALL XR

Strategy is delivering

- 8 global products driving growth
  - Focused on meeting customers' needs
- Extending our geographic reach
  - Proposed acquisition of Movetis NV adds to core GI business
- Pipeline progress in key development programs
- Well placed to absorb industry macro challenges
- Full year earnings trending towards $4.00 per share
  - 15% increase on 2009
- Strongly supporting our long term aspirational target
  - Mid-teens sales growth on average between 2009 - 2015

Financial Review

Graham Hetherington
CFO

Delivering excellent Q2 results

	Q2 2010 $m	Q2 2009 $m	Reported Growth	Like for Like Growth (2)
Total Revenues	849	630	+35%	+37%
EBITDA (1)	294	140	+110%	+114%
EPS - ADS (1)	$1.03	$0.60	+71%	
Cash generation (1)	416	192	+117%	

(1) These are Non GAAP financial measures. See appendix for a list of items excluded from the US GAAP equivalent used to calculate these measures.
(2) 'Like for Like Growth' excludes movements in exchange rates by applying 2009 exchange rates to 2010 results.

2010 Q2 Revenue summary

	Q2 2010 $m	Q2 2009 $m	Reported Growth	Like for Like Growth (2)
Core Product Sales (1)	684	491	+39%	+42%
ADDERALL XR Sales	80	67	+19%	+18%
Total Product Sales	764	558	+37%	+39%
Royalties and Other Revenues	85	72	+19%	+20%
Total Revenues	849	630	+35%	+37%

(1) Core product sales represent Shire's product sales excluding ADDERALL XR.
(2) 'Like for Like Growth' excludes movements in exchange rates by applying 2009 exchange rates to 2010 results.

2010 Q2 Core products growing revenues



Operating leverage emerging – Key financial ratios

Year on Year:	Q2 2010	Q2 2009
Total Product Sales	+37%	-21%
Core Product Sales	+39%	+20%
R&D(1)	+22%	-7%
SG&A(1)	+7%	-5%

Ratios:

% of Total Product Sales			
R&D(1)	19%	⟵	21%
SG&A(1)	40%	⟵	51%
% of Core Product Sales			
R&D(1)	21%	⟵	24%
SG&A(1)	44%	⟵	58%

(1) These are Non GAAP financial measures. See appendix for a list of items excluded from the US GAAP equivalents used to calculate these measures.

Q2 2010 - Cashflow

Millions of USD



Cash, cash equivalents and restricted cash at December 31, 2009	532
Cash inflow to June 30, 2010	177
Cash, cash equivalents and restricted cash at June 30, 2010	709
Convertible Debt	(1,100)
Building finance obligation	(7)
Net debt at June 30, 2010(2)	**(398)**

(1) See appendix for definition.

(2) Shire has a revolving credit facility of $1.2bn which was undrawn at June 30, 2010.

ADDERALL XR dynamics

Macro assumption:

- Citizen Petition holds through 2010



FY 2010 Dynamics versus Q2 2010

(see appendix for detailed analysis)

US Product Sales:

Demand sales	↓	Potential for brand erosion by authorized generics
Supply Chain stock	↓	Destocking due to lower demand
Sales deductions	↑	Rebate post Healthcare Reform trending towards upper end of 60–70% range

Other Sales:

Canada	↓	Promotion behind newly launched VYVANSE
Teva/Impax	=	

Royalties:

Impax	↓	- Pipeline inventory stabilising, higher gross to net deductions +/- Impax share movements

Shire 2010 Outlook improves

Full year 2010 Dynamics

Direction Versus FY 09 (see Appendix for more analysis)

ABSORBING THE IMPACT OF:
- **US Healthcare reform**
- **European Pricing**
- **Financial impact of Movetis acquisition**
- **Foreign exchange rate movements to date**

	Direction	
Core Product Sales	↑	• Continued growth against strengthening comparatives • REPLAGAL year on year growth moderating
Total Product Sales	↑	Core product growth > AXR decline
Royalties	↑	AXR royalties offset declines in other royalties
Gross Margins	=	
R&D and SG&A	↑	• Increasing investment behind long term growth • Top end of 5-10% year on year growth guidance • Operating leverage
Tax rate	=	Broadly 25%
Reported EPS-ADS	↑	**FY 10 trending towards $4.00 per ADS**

Note: Sensitivity to Forex Movements:

	EPS-ADS $
A 10 cent strengthening of the $ against the €	-0.09
A 10 cent strengthening of the $ against the £	0.03
	-0.06

Memo: Interest on convertible = $34m pa

Specialty Pharma update

Michael Cola
President, Specialty Pharmaceuticals

Shire

Our purpose
We enable people with life-altering conditions to lead better lives

Specialty Pharma – Strategic direction

Recent Past

- SP was primarily a one product, one market focused organization

Today's Performance and Prospects Driven By:

- Multiple products in rapidly growing ADHD market
- Globalization efforts to bring SP products to more patients
- Investments in new uses for existing products coupled with unique new pipeline candidates

Multiple products in rapidly growing ADHD market

- In the US, VYVANSE demonstrated outstanding growth in Q2-10
  - Net Sales up 27% (vs. Q2-09)
  - TRx Volume up 29% (vs. Q2-09)
  - Market Growth up 12% (vs. Q2-09)
- INTUNIV launch meeting our expectations
  - National market share was 2.6% as of July 23
  - Significantly higher in the important child / adolescent psychiatry and general psychiatry subsets of prescribers
  - Over 18,000 physicians have prescribed INTUNIV
  - INTUNIV is drawing business from multiple sources
  - 10% of patients starting INTUNIV are new to market, 37% are switches, and 53% are add on therapy (Source: SDI, April 2010)
  - ~40% of switches are coming from Strattera, other Alpha 2s, or antipsychotics (Source: SDI, April 2010)
- EQUASYM providing an excellent footprint into European ADHD market

Globalization efforts to bring SP products to more patients

- VYVANSE in Canada off to a strong start – 3.8% share after 5 months
- VYVANSE (VENVANSE) approved in Brazil in July; launch planned for H1-11; First approval outside of N America
- VYVANSE's European pivotal trials more than 50% enrolled
- Advancing a guanfacine-based product candidate for the EU
- Progressing Phase 3 development efforts for XAGRID in Japan

Proposed Movetis acquisition: Strong strategic fit with Shire's growing core GI business

- Movetis: Belgian, GI specialty company created in 2006
  - J&J spin off of the Janssen GI small molecule pipeline
    - Foremost experts on motility disorders in the industry
- RESOLOR - Exciting addition to GI franchise
  - Addresses a symptomatic unmet need and is uniquely positioned to treat chronic constipation
  - Unique pro-kinetic Mechanism of Action (MOA): selective 5-HT_4 agonist
    - NCE with CoM patent protection to 2020
  - Potential for additional upside for RESOLOR in follow-on populations (e.g., pediatrics and males) and new indications (e.g., opioid induced constipation)
- Substantial GI pipeline and product development expertise

R&D pipeline – new indications for existing products

- VYVANSE
  - Pending indication for adolescent* ADHD will provide platform to address adolescent to adult transition, upon approval
  - Depression Augmentation – headline results, H2-10
  - Negative Symptoms of Schizophrenia, Cognitive Impairment in Depression and Excessive Daytime Sleepiness – headline results, H1-11

- INTUNIV
  - Co-administration study with Stimulants met all primary and secondary endpoints
  - sNDA to seek approval as adjunctive treatment with long-acting stimulants filed with FDA in Q2-10; Approval projected for H1-11
  - Stimulant + Non-Stimulant co-administration is a distinct patient segment representing 12% of treated ADHD patients and is growing 20% annually

- LIALDA/MEZAVANT
  - SPD 476 for Diverticular disease - trial fully enrolled
  - 2 year trial – data expected in 2012

* Subject to regulatory approval

R&D pipeline – early stage projects

- Guanfacine CarrierWave (GCW; SPD 547)
  - Completed feasibility study in humans using microdosing
    - Results indicate characteristics suitable for entering formal Ph 1 studies
    - Ph1 studies will initiate Q3-10 with results throughout 2011
  - GCW could potentially improve on current guanfacine profile to minimize known food, GI and sedation effects

- SPD 535 – novel platelet lowering agent
  - Initial Proof-of-concept program targets prevention of thrombotic complications associated with arteriovenous grafts in hemodialysis
    - Proof-of-principle for broader utility as an anti-coagulant
    - Data available Q3-10

HGT update

Sylvie Grégoire
President, Human Genetic Therapies

Strong VPRIV launch continues with approximately 850 patients currently on therapy [1]



Note: [1] As at 29 July 2010

[2] Non-paying patients include patients enrolled in ongoing clinical trials, treatment IND patients in the US and certain EAP patients in the rest of the world

- Number one priority is to ensure uninterrupted long term access to treatment for patients currently on VPRIV
- Capacity to support approximately 1000 VPRIV patients in 2010
- Currently implementing a program to monitor and manage requests from new patients
- Positive CHMP opinion in the EU in June

Strong REPLAGAL performance with over 320 patients added in Q2



Note: (1) As at 29 July 2010. Includes commercial patients, emergency IND patients, treatment IND patients and patients currently enrolled in ongoing clinical trials

- Approximately 2000 patients currently on therapy (1)
  - Doubling of patients on REPLAGAL in past 12 months
- Capacity to add 150 -250 additional Fabry patients in 2010 and to add 250-350 phased throughout 2011
- Estimated 70% market share in EU
- Gathering additional clinical data - BLA withdrawn

ELAPRASE growth continues to be driven by increasing penetration in newer markets and further geographic expansion



- Q2 highlights
  - Revenues of $100m
  - Over 1000 patients on therapy
  - Roller bottle manufacturing facility approved by FDA
- Future growth driven largely by increased penetration, particularly in newer markets (CEEC, MEA & LATAM)

HGT – Other highlights

- FIRAZYR
  - Now launched in 18 countries, including the 5 largest European countries
  - Self administration study completed
    - Labelling change filing in EU targeted for Q4 2010
  - US Complete Response submission targeted for H1 2011
- Sanfilippo A
  - Phase I/II trial initiated
- Initiated manufacturing activities in new facility in Lexington

Concluding remarks

Angus Russell
CEO

H2 2010 Key events

- VYVANSE update from Ph2 non-ADHD trials
- SPD 535 (novel platelet lowering agent) PoC update
- VPRIV EU Commission decision/approval
- FIRAZYR self administration filing

Delivering growth now and into the future

- Delivering excellent results
  - Total revenues up 35%
  - 2010 full year earnings per ADS trending towards $4.00
- Executing on our strategy
  - Driving growth from balanced portfolio of 8 global products
  - Proposed acquisition of Movetis NV
  - Developing and progressing our pipeline
  - Increasing our global reach
- Strongly positioned to continue growth
- Aspiration to grow sales in the mid-teens range on average between 2009 and 2015

*Core products represent Shire's products excluding ADDERALL XR

Questions and Answers

APPENDIX

2010 Q2 Key financial ratios

FINANCIAL RATIOS	Q2 2010	y-o-y Growth	Q2 2009	y-o-y Growth
% of product sales				
Product sales	$764m	37%	$558m	-21%
Gross margin	86%		84%	
R&D	19%	22%	21%	-7%
SG&A	40%	7%	51%	-5%
EBITDA[(1)] (% of product sales)	27%		12%	
EBITDA[(2)] (% total revenue)	35%	110%	22%	-47%
% of core product sales				
Core product sales	$684m	39%	$491m	20%
R&D	21%		24%	
SG&A	44%		58%	

(1) Excluding royalties and other revenues.
(2) Including royalties and other revenues.
This slide contains Non GAAP financial measures. See appendix for a list of items excluded from the US GAAP equivalent used to calculate these measures.

2010 Emerging shape of Shire income statement

	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2009 FY	2010 Q1	2010 Q2	Direction V. FY 09	2010 Dynamics
Core product sales	$459m	$491m	$532m	$585m	$2,067m	$626m	$684m	↑	•Continued growth against strengthening comparatives •REPLAGAL year on year growth moderating
versus prior year	+24%	+20%	+20%	+36%	+25%	+36%	+39%		
Total product sales	$756m	$558m	$603m	$777m	$2,694m	$718m	$764m	↑	Core product growth > AXR decline
versus prior year	+20%	-21%	-15%	+10%	-2%	-5%	+37%		
Royalties	$51m	$67m	$60m	$115m	$293m	$95m	$83m	↑	AXR royalties offset declines in other royalties
versus prior year	-22%	+3%	-1%	+109%	+19%	+88%	+24%		
Gross margin (1) (2)	89%	84%	84%	87%	86%	87%	86%	=	
R&D (2)	$117m	$118m	$144m	$144m	$523m	$127m	$143m	↑	•Increasing investment behind long term growth •Top end of 5-10% year on year growth guidance •Operating leverage
versus prior year	+$9m	-$9m	+$27m	+$21m	+$48m	+$10m	+$25m		
SG&A (2)	$271m	$285m	$267m	$315m	$1,138m	$309m	$304m		
versus prior year	-$27m	-$14m	-$16m	+$26m	-$31m	+$37m	+$19m		
Tax Rate (2)	24%	2%	33%	31%	25%	26%	25%	=	•Broadly 25%

(1) Gross margin calculated as a percentage of product sales
(2) These are Non GAAP financial measures. See appendix for a list of items excluded from the US GAAP equivalents used to calculate these measures.

2010 Emerging shape of Shire income statement - Normalised Medicaid Rebate

	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2009 FY	2010 Q1	2010 Q2	Direction V. FY 09	2010 Dynamics
Core product sales	$459m	$491m	$532m	$585m	$2,067m	$626m	$684m	↑	•Continued growth against strengthening comparatives •REPLAGAL year on year growth moderating
versus prior year	+24%	+20%	+20%	+36%	+25%	+36%	+39%		
Total product sales	***$793m***	***$557m***	***$641m***	***$703m***	$2,694m	$718m	$764m	↑	Core product growth > AXR decline
versus prior year	***+26%***	***-21%***	***-10%***	***0%***	-2%	***-9%***	***+37%***		
Royalties	$51m	$67m	$60m	$115m	$293m	$95m	$83m	↑	AXR royalties offset declines in other royalties
versus prior year	-22%	+3%	-1%	+109%	+19%	+88%	+24%		
Gross margin [1] [2]	***90%***	***84%***	***85%***	***86%***	86%	87%	86%	=	
R&D [2]	$117m	$118m	$144m	$144m	$523m	$127m	$143m	↑	•Increasing investment behind long term growth •Top end of 5-10% year on year growth guidance •Operating leverage
versus prior year	+$9m	-$9m	+$27m	+$21m	+$48m	+$10m	+$25m		
SG&A [2]	$271m	$285m	$267m	$315m	$1,138m	$309m	$304m		
versus prior year	-$27m	-$14m	-$16m	+$26m	-$31m	+$37m	+$19m		
Tax Rate [2]	24%	2%	33%	31%	25%	26%	25%	=	•Broadly 25%

(1) Gross margin calculated as a percentage of product sales
(2) These are Non GAAP financial measures. See appendix for a list of items excluded from the US GAAP equivalents used to calculate these measures.

2010 Q2 XR dynamics

	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2010 Q1	2010 Q2	Direction Versus Q2 10	2010 Dynamics
TRx ('000s)[1]	2,288	1,222	914	954	961	951		
Value per Rx	$209.53	$210.20	$229.20	$226.44	$225.39	$225.85		
Demand Sales[1]	$479m	$257m	$210m	$216m	$217m	$214m	↓	Potential for brand erosion by authorized generics
Supply Chain stocking/(destocking)	($16m)	($76m)	($3m)	$13m	($22m)	$33m	↓	Destocking due to lower demand
Gross Sales	**$463m**	**$181m**	**$207m**	**$229m**	**$195m**	**$247m**		
Sales Deductions	($173m)	($131m)	($151m)	($52m)	($120m)	($183m)	↑	Rebates post Healthcare Reform trending towards upper end of 60–70% range
as % of Gross Sales	37%	72%	73%	23%	61%	74%		
Net Sales - US	**$290m**	**$50m**	**$56m**	**$177m**	**$75m**	**$64m**		
Net Sales - Canada	$6m	$6m	$6m	$9m	$9m	$7m	↓	Promotion behind newly launched VYVANSE
Net Sales - Teva/Impax	-	$11m	$9m	$6m	$8m	$9m		
Total Product Revenue	**$296m**	**$67m**	**$71m**	**$192m**	**$92m**	**$80m**		
XR Royalties	-	$14m	$2m	$52m	$41m	$28m	↓	-Pipeline inventory stabilising, higher gross to net deductions +/- Impax share movements
Total Revenues	**$296m**	**$81m**	**$73m**	**$244m**	**$133m**	**$108m**		

Key assumptions: CP holds through 2010; States continue to invoice for Medicaid rebates at 2009 levels; and AXR quota available.

[1] Restated to include non IMS retail sales

2010 Q2 XR dynamics – normalised Medicaid Rebate

	2009 Q1	2009 Q2	2009 Q3	2009 Q4	2010 Q1	2010 Q2	Direction Versus Q2 10	2010 Dynamics
TRx ('000s)[1]	2,288	1,222	914	954	961	951		
Value per Rx	$209.53	$210.20	$229.20	$226.44	$225.39	$225.85		
Demand Sales[1]	$479m	$257m	$210m	$216m	$217m	$214m	↓	Potential for brand erosion by authorized generics
Supply Chain stocking/(destocking)	($16m)	($76m)	($3m)	$13m	($22m)	$33m	↓	Destocking due to lower demand
Gross Sales	**$463m**	**$181m**	**$207m**	**$229m**	**$195m**	**$247m**		
Sales Deductions	***($136m)***	***($132m)***	***($113m)***	***($126m)***	($120m)	($183m)	↑	Rebates post Healthcare Reform trending towards upper end of 60–70% range
as % of Gross Sales	***29%***	***73%***	***55%***	***55%***	61%	74%		
Net Sales - US	**$327m**	**$49m**	**$94m**	**$103m**	**$75m**	**$64m**		
Net Sales - Canada	$6m	$6m	$6m	$9m	$9m	$7m	↓	Promotion behind newly launched VYVANSE
Net Sales - Teva/Impax	-	$11m	$9m	$6m	$8m	$9m		
Total Product Revenue	**$333m**	**$66m**	**$109m**	**$118m**	**$92m**	**$80m**		
XR Royalties	-	$14m	$2m	$52m	$41m	$28m	↓	-Pipeline inventory stabilising, higher gross to net deductions +/- Impax share movements
Total Revenues	**$333m**	**$80m**	**$111m**	**$170m**	**$133m**	**$108m**		

Key assumptions: CP holds through 2010; States continue to invoice for Medicaid rebates at 2009 levels; and AXR quota available .

[1] Restated to include non IMS retail sales

2010 Q2 Portfolio Strength and Diversity – Core product sales

	Q2 2010 $m	Q2 2009 $m	Reported Growth	Like for Like Growth[2]
VYVANSE	148	114	+30%	+29%
ELAPRASE	100	85	+17%	+20%
REPLAGAL	82	44	+84%	+93%
LIALDA / MEZAVANT	70	55	+27%	+27%
PENTASA	61	54	+12%	+12%
INTUNIV	51	-	n/a	n/a
FOSRENOL	45	50	-9%	-7%
VPRIV	29	-	n/a	n/a
FIRAZYR	3	2	+73%	+86%
OTHER	95	87	+10%	+13%
CORE PRODUCT SALES [1]	**684**	**491**	**+39%**	**+42%**

(1) Core product sales represent Shire's product sales excluding ADDERALL XR.
(2) 'Like for Like Growth' excludes movements in exchange rates by applying 2009 exchange rates to 2010 results.

2010 Q2 Core product sales growth

Q2 2008
$409m



Q2 2010
$684m





Core product sales represent Shire's product sales excluding ADDERALL XR.

2010 Q2 Royalties

	Q2 2010 $m	Q2 2009 $m	Reported Growth
3TC and ZEFFIX	38	39	-3%
ADDERALL XR	28	14	+102%
REMINYL	11	11	0%
Other	6	3	+100%
Total Royalties	**83**	**67**	**+24%**

2010 Q2 Cash generation reconciliation

	Q2 2010 $m	Q2 2009 $m
Net cash provided by operating activities	**284**	**72**
Tax and interest payments (net)	128	83
Payments for acquired and in-licensed products	-	37
Foreign exchange on cash	4	-
Non GAAP cash generation	**416**	**192**

Non GAAP measures

- This presentation contains financial measures not prepared in accordance with US GAAP.
- These Non GAAP financial measures are used by Shire's management to make operating decisions because they facilitate internal comparisons of the Company's performance to historical results and to competitors' results. They should not be considered in isolation from, as substitutes for, or superior to financial measures prepared in accordance with US GAAP.
- The following items are excluded from these non-GAAP financial measures:

Amortization and asset impairments:

- Intangible asset amortization and impairment charges and;
- Other than temporary impairment of investments.

Acquisitions and integration activities:

- Upfront payments and milestones in respect of in-licensed and acquired products;
- Costs associated with acquisitions, including transaction costs, and fair value adjustments on contingent consideration and acquired inventory and;
- Costs associated with the integration of companies

Divestments, re-organizations and discontinued operations:

- Gains and losses on the sale of non-core assets;
- Costs associated with restructuring and re-organization activities;
- Termination costs; and
- Income / (losses) from discontinued operations.